Serious but Less Common Side Effects: Pancreatitis: There is a risk of pancreatitis (inflammation of the pancreas), which is typically associated with a history of pancreatic disorders
The most common side effects of tirzepatide are gastrointestinal: Nausea: Reported by 12-33% of participants depending on dose (most common early in treatment) Diarrhea: 12-21% of participants Constipation: 6-11% of participants Vomiting: 5-13% of participants Decreased appetite: Expected therapeutic effect but can be uncomfortable These side effects are typically most intense during the first few weeks at each new dose level and tend to improve as the body adjusts
For the first time, patients can access a GLP-1 medication in pill form without meal restrictions, at a price point well below existing injectables
GLP-1 receptor activation enhances insulin signaling, activates AMPK, and suppresses inflammatory cascades, improving cellular energy balance and reducing metabolic stress
Retatrutide (CAS 2381089-83-2) is a triple-agonist peptide that engages three receptors simultaneously the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor making it one of the most-studied multi-receptor metabolic peptides currently in the research literature
